These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26317265)

  • 41. H3K9me-enhanced DNA hypermethylation of the p16INK4a gene: an epigenetic signature for spontaneous transformation of rat mesenchymal stem cells.
    Zheng Y; He L; Wan Y; Song J
    Stem Cells Dev; 2013 Jan; 22(2):256-67. PubMed ID: 22873822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
    Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
    J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
    Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
    Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
    Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
    [TBL] [Abstract][Full Text] [Related]  

  • 45. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
    Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overexpression of enhancer of zests homolog 2 in lymphoma.
    Guo SQ; Zhang YZ
    Chin Med J (Engl); 2012 Oct; 125(20):3735-9. PubMed ID: 23075734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polycomb recruitment at the Class II transactivator gene.
    Boyd NH; Morgan JE; Greer SF
    Mol Immunol; 2015 Oct; 67(2 Pt B):482-91. PubMed ID: 26283540
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiation.
    Heinen A; Tzekova N; Graffmann N; Torres KJ; Uhrberg M; Hartung HP; Küry P
    Glia; 2012 Nov; 60(11):1696-708. PubMed ID: 22821416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
    Eich ML; Athar M; Ferguson JE; Varambally S
    Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
    Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
    Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
    Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
    Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
    Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
    FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
    Bradley WD; Arora S; Busby J; Balasubramanian S; Gehling VS; Nasveschuk CG; Vaswani RG; Yuan CC; Hatton C; Zhao F; Williamson KE; Iyer P; Méndez J; Campbell R; Cantone N; Garapaty-Rao S; Audia JE; Cook AS; Dakin LA; Albrecht BK; Harmange JC; Daniels DL; Cummings RT; Bryant BM; Normant E; Trojer P
    Chem Biol; 2014 Nov; 21(11):1463-75. PubMed ID: 25457180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2.
    Li Z; Xu L; Tang N; Xu Y; Ye X; Shen S; Niu X; Lu S; Chen Z
    FEBS Lett; 2014 Aug; 588(17):3000-7. PubMed ID: 24928441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
    Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
    Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
    Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
    Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
    Varambally S; Cao Q; Mani RS; Shankar S; Wang X; Ateeq B; Laxman B; Cao X; Jing X; Ramnarayanan K; Brenner JC; Yu J; Kim JH; Han B; Tan P; Kumar-Sinha C; Lonigro RJ; Palanisamy N; Maher CA; Chinnaiyan AM
    Science; 2008 Dec; 322(5908):1695-9. PubMed ID: 19008416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The potential roles of EZH2 in regenerative medicine.
    Chou RH; Chiu L; Yu YL; Shyu WC
    Cell Transplant; 2015; 24(3):313-7. PubMed ID: 25647295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EZH2 is essential for development of mouse preimplantation embryos.
    Huang XJ; Wang X; Ma X; Sun SC; Zhou X; Zhu C; Liu H
    Reprod Fertil Dev; 2014 Oct; 26(8):1166-75. PubMed ID: 24153105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.